

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED

PART-I

31ST DECEMBER 2013

(₹ In Lacs)

Sr. No.	Particulars	Quarter ended 31.12.2013 (Unaudited)	Quarter ended 30.09.2013 (Unaudited)	Quarter ended 31.12.2012 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	19,171	19,863	15,312	54,126	47,442	63,767
	(b) Excise Duty	(330)	(358)	(286)	(975)	(847)	(1,124)
	(c) Net Sales / Income from Operations (a-b)	18,841	19,505	15,026	53,151	46,595	62,643
	(d) Other Operating Income	(60)	725	309	1,258	557	396
	Total Income from Operations (Net) (c+d)	18,781	20,230	15,335	54,409	47,152	63,039
2	Expenses						
	(a) Cost of materials consumed	5,226	6,320	5,843	16,825	17,259	22,328
	(b) Purchases of stock-in-trade	905	1,316	844	3,195	2,754	3,555
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade*	1,109	(64)	(339)	760	(202)	313
	(d) Employee Benefits expense	3,223	3,339	2,553	9,445	7,527	10,031
	(e) Depreciation and Amortisation expense	802	772	572	2,307	1,747	2,372
	(f) Research & Development Expense	367	384	326	1,025	1,011	1,290
	(g) Other Expenses	4,966	5,634	4,180	14,433	12,023	16,215
	Total Expenses	16,598	17,701	13,979	47,990	42,119	56,104
3	Profit from Operations before Other Income, finance costs and Exceptional Items (1-2)	2,183	2,529	1,356	6,419	5,033	6,935
4	Other Income	11	42	42	68	72	89
5	Profit from ordinary activities before finance costs and Exceptional Items (3+4)	2,194	2,571	1,398	6,487	5,105	7,024
6	Finance Costs	386	526	501	1,535	1,694	2,187
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	1,808	2,045	897	4,952	3,411	4,837
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary activities before tax (7-8)	1,808	2,045	897	4,952	3,411	4,837
10	Tax Expenses	396	441	159	1,018	430	571
11	Net Profit from Ordinary activities after tax (9-10)	1,412	1,604	738	3,934	2,981	4,266
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	1,412	1,604	738	3,934	2,981	4,266
14	Paid up Equity Share Capital (Face value of Equity Share - in ₹)	1,843 2	1,843 2	1,843 2	1,843 2	1,843 2	1,843 2
15	Reserves excluding Revaluation Reserves as per Balance Sheet of Previous accounting year						39,561
16	Earnings per share (before and after extraordinary items) (of Face Value ₹ 2/- each) (not annualised):						
	(a) Basic	1.53	1.74	0.80	4.27	3.23	4.63
	(b) Diluted	1.53	1.74	0.80	4.27	3.23	4.63

PART- II Select Information for the Quarter and nine months ended 31st December, 2013

Sr. No.	Particulars	Quarter ended 31.12.2013 (Unaudited)	Quarter ended 30.09.2013 (Unaudited)	Quarter ended 31.12.2012 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of Shares	375,78,444	375,72,344	376,05,715	375,78,444	376,05,715	376,05,715
	- Percentage of Shareholding	40.78	40.77	40.81	40.78	40.81	40.81
2	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	545,71,911	545,78,011	545,44,640	545,71,911	545,44,640	545,44,640
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	59.22	59.23	59.19	59.22	59.19	59.19
B	INVESTOR COMPLAINTS	3 months ended 31.12.2013					
	Pending at the beginning of the quarter		Nil				
	Received during the quarter		0				
	Disposed of during the quarter		0				
	Remaining unresolved at the end of the quarter		Nil				

Notes :

1. The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lacs)

Net Sales and Income from Operations	Quarter ended 31.12.2013 (Unaudited)	Quarter ended 30.09.2013 (Unaudited)	Quarter ended 31.12.2012 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2012 (Unaudited)	Year ended 31.03.2013 (Audited)
India	12,067	12,759	9,834	35,227	31,079	40,772
Outside India	6,774	6,746	5,192	17,924	15,516	21,871
Total	18,841	19,505	15,026	53,151	46,595	62,643

2. The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 29th January, 2014.

3. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2013.

4. The figures for previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board
For Indoco Remedies Ltd
Sd/-
Suresh G. Kare
Chairman

Place : Mumbai

Date : 29th January, 2014

Regd. Office: Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098
Tel: + 91-22-2654 1851/55 Fax: +91-22-66936241